Combining Immune Checkpoint Inhibitors with Standard Therapy for Cervical Cancer
Author Information
Author(s): Zhang Xinmiao, Shen Jinhai, Huang Mengfan, Li Rongxia
Primary Institution: College of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine
Hypothesis
This study aims to evaluate the therapeutic efficacy and safety of adding immune checkpoint inhibitors to standard therapy in the treatment of recurrent or advanced cervical cancer.
Conclusion
The combination of immune checkpoint inhibitors with standard therapy shows superior efficacy and a comparable toxicity profile for treating recurrent or advanced cervical cancer.
Supporting Evidence
- The addition of immune checkpoint inhibitors significantly improved progression-free survival and overall survival compared to standard therapy alone.
- Patients treated with the combination therapy experienced a modest increase in grade 3-5 adverse events.
- Subgroup analyses indicated that younger patients and those with non-metastatic disease benefited more from the combination therapy.
Takeaway
Doctors found that using new cancer drugs called immune checkpoint inhibitors along with regular treatments helps patients with cervical cancer live longer and feel better, but it can also cause some side effects.
Methodology
Data from four phase 3 clinical trials were analyzed using meta-analyses to combine hazard ratios for overall survival and progression-free survival, odds ratios for the objective response rate, and relative risks for adverse events.
Potential Biases
One trial had a high risk of performance bias due to being open-label, while others had low risk across assessed criteria.
Limitations
Inconsistent reporting of adverse events across studies and discrepancies in PD-L1 assessment techniques.
Participant Demographics
The study included 2,857 patients with recurrent or advanced cervical cancer, with varying ages and cancer stages.
Statistical Information
Confidence Interval
{"overall_survival":"0.58-0.75","progression_free_survival":"0.60-0.75","objective_response_rate":"1.13-1.94","adverse_events":"1.03-1.13"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website